Recursion Pharmaceuticals Before Q4 Earnings: How to Play the Stock

Recursion Pharmaceuticals (RXRX) is expected to report its fourth-quarter 2024 results soon. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is pegged at $28.73 billion. The consensus mark for RXRX’s loss per share is pinned at 36 cents.See the Zacks Earnings Calendar to stay ahead of market-making news.In the past 60 days, the Zacks Consensus Estimate for Recursion’s 2024 loss per share has remained constant at$1.57. During the same time frame, the company’s 2025 loss for ...